Atrial Fibrillation
Conditions
Keywords
Atrial fibrillation, VKA, Stroke
Brief summary
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.
Interventions
DRUGRivaroxaban (Xarelto, BAY59-7939)
As prescribed by treating physicians
As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Older than 18 years * Diagnosis of non-valvular AF (ICD code 427.31) * Pharmacological treatment with VKAs or rivaroxaban following diagnosis
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of stroke | 12 months | Presence of stroke prior and subsequent to treatment |
| Active substance received | 12 months | Rivaroxaban or VKAs (Acenocoumarol and Warfarin) |
| Time in therapeutic range (TTR) values in the last 6 months | 6 months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of treatment (in days) | 12 months | — |
| Frequency of the prescribed treatment (in hours) | 12 months | — |
| Dose of the prescribed treatment | 12 months | — |
| Date of stroke | 12 months | — |
| Type of stroke | 12 months | Type of stroke acccording to patients group: unknown, haemorrhagic or ischaemic. |
Other
| Measure | Time frame |
|---|---|
| Date of AF diagnosis | 12 months |
| Comorbidities | 12 months |
Countries
Spain
Outcome results
None listed